Gamifant

Chemical Nameemapalumab-lzsg
Dosage FormInjection: (intravenous; 10 mg/2 mL, 50 mg/10 mL)
Drug ClassMonoclonal antibodies
SystemBlood
CompanySobi Inc.
Approval Year2018

Indication

  • To treat primary refractory, recurrent, or progressive hemophagocytic lymphohistiocytosis.
  • To treat primary hemophagocytic lymphohistiocytosis in patients with intolerance to conventional hemophagocytic lymphohistiocytosis therapy.
Last updated on 10/13/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Gamifant (Emapalumab-lzsg) Prescribing Information 2018Sobi Inc., Waltham, MA
Document TitleYearSource
Emapalumab in children with primary hemophagocytic lymphohistiocytosis. 2020The New England Journal of Medicine